Krishna Institute Of Medical Sciences Limited · NSE:KIMS
Krishna Institute Of Medical Sciences — Q1 FY2022 Earnings Presentation
29 slides from Krishna Institute Of Medical Sciences's earnings presentation, Aug 10, 2021
Slide 1: Investor presentation filing letter to stock exchanges
\KKIMS ,' HOSPITALS" 10'" August, 2021 CIN: L55101TG197JPLC040558 The General Manager, The Manager, DepartmentofCorpotateservices ListingDepartment Bombay Stock Exchange Ltd (BSE) Narional Stock Exchaoge oflndia Limited, Phiroze Jheejheebhoy Torvets, ] Exchange Plaza, 5th Floor, Dalal sreer. I Plor
Slide 2: Q1 FY-2022 Earnings Update
NELLOR RAJAHMUNDRY ONGOL SRIKAKULA E E M SECUNDERABA KONDAPU VIZA ANANTAPU KURNOOL D R G R The Largest Corporate Healthcare Group in Andhra Pradesh and Telangana Q1 FY-2022 Earnings Update Krishna Institute of Medical Sciences Limited August 2021 1 Private & Confidential
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Krishna Institute of Medical Sciences Limited (“KIMS” or the “Company”) solely for your information and for your use and may not be taken away, distributed, reproduced, or redistributed or passed on, directly or indirectly, to any other person (wheth
Slide 4: Four Cornerstones of Our Vision
FOUR CORNERSTONES OF OUR VISION Tertiary & Affordable Doctor Modern Quaternary Quality participation Medical services Care model Technology Providing affordable quality care using modern medical technology through comprehensive tertiary & quaternary services by engaging doctors with a unique partici
Slide 5: Our Key Strengths
OUR KEY STRENGTHS Regional Leadership - Cluster based approach Clinical outcome driven excellence Affordable Quality Care Ability to attract, train and retain high quality doctors, consultants and medical support staff Track record of strong operational and financial performance 4 Private & Confiden
Slide 6: KIMS at a Glance
KIMS AT A GLANCE OUR KIMS HOSPITALS TEAM Doctors Nurses Paramedics Admin 1136(1) 2860(2) 1636(3) 4569(4) Srikakulam (200) Vizag (434) STRATEGIC FOCUS ON SOUTH INDIA MARKET Secunderabad (1,000) With 20+ years of experience, KIMS has a strong understanding of Kondapur (200) • Regional nuances • Mind-s
Slide 7: Centres of Excellence
CENTRES OF EXCELLENCE Cardiac Neuro Gastro Renal Sciences Sciences Sciences Sciences Ortho Onco Organ Mother & Sciences Sciences Transplant Child OUR OTHER SPECIALITIES: • Anaesthesiology • Intensive Care • Pain Management • Accident & Emergency Care • Internal Medicine • Physiotherapy & Rehabilitat
Slide 8: Key Clinical Achievements - Over Years
KEY CLINICAL ACHIEVEMENTS - OVER YEARS Over 1000 successful Epilepsy surgeries done Over 1,000 kidney transplants done, led by India’s first successful double lung transplant Padmashri Dr. Sahariah on a COVID patient at KIMS Secunderabad Largest SPEN tumour (6X7 cm) removed from - Over 50+ Lung Tran
Slide 9: Key Clinical Achievements – Quarter
KEY CLINICAL ACHIEVEMENTS – QUARTER 1 Preterm baby weighing 1100 grams successfully Complex Knee Replacement surgery performed on underwent a heart procedure. 56 yr old women. Rare Kidney transplant between two non- Infant born with a rare & complex Rh issue compatible blood groups successfully done
Slide 10: Academics & Research
ACADEMICS & RESEARCH • The KIMS Foundation and Research Centre CLINICAL RESEARCH (KFRC) were founded in 2010 • No. of Clinical Trials till date - 263 • KFRC laboratories are located in KIMS premises • No. of In-house Projects - 45 and function as an autonomous research • No. of DNB Thesis Projects -
Slide 11: COVID-19 Update
COVID-19 UPDATE • The COVID second wave ravaged the country during April & RT PCR May 21. Tests: 1,22,000+ • With learnings from first wave, our 9 hospitals were better prepared to handle COVID cases. COVID Patients treated: 20,000+ • We installed: -Additional Liquid Oxygen Tank (20,000 Ltr) taking
Slide 12: COVID - Clinical Achievements
COVID - CLINICAL ACHIEVEMENTS • Over 50+ COVID patients were airlifted to KIMS Secunderabad for lung transplants from across the country - Over 10+ were COVID Positive Doctors from across the country • Over 70+ COVID patients treated on ECMO. • 4 year girl with COVID successfully undergoes life thre
Slide 13: KIMS in News - Q1FY22
KIMS IN NEWS - Q1FY22 12 Private & Confidential
Slide 14: Modern Medical Technology
MODERN MEDICAL TECHNOLOGY 4-Arm HD da Vinci O-Arm Scanner Spy Glass Robotic Surgical Multi-dimensional surgical State of the art add on to System imaging platform optimized ERCP that allows doctors Facilitates complex for use in spine, to observe patients’ biliary surgeries that are virtually orthop
Slide 15: Operational Performance
OPERATIONAL PERFORMANCE IP Volumes ALOS (days) YoY FY 22 Q1 Vs FY 21 Q1 : 37% QoQ FY 22 Q1 Vs FY 21 Q4: (3%) 1,40,676 32,732 31,709 1,16,592 5.5 5.5 5.0 5.1 23,203 4.3 FY20 FY21 Q1 FY21 Q4 FY21 Q1 FY22 FY20 FY21 Q1 FY21 Q4 FY21 Q1 FY22 OP Volumes ARPOB (Rs.) YoY FY 22 Q1 Vs FY 21 Q1 : 40% QoQ FY 22
Slide 16: Operational Performance
OPERATIONAL PERFORMANCE Arogyasri, 11% Arogyasri, 8% Corporates, 6% Corporates, 11% Cash,63% Cash,64% Payer Profile FY 21 Q1 FY 22 Insurance, 23% Insurance, 16% 15 Private & Confidential
Slide 17: Financial Performance
FINANCIAL PERFORMANCE (RS. MILLIONS) REVENUE EBITDA 22% 28% 20% 29% 31% 4,775 3,810 13,401 3,627 1,479 2,511 1,051 2,055 11,287 401 FY20 FY21 Q1 FY 21 Q4 FY21 Q1 FY22 FY20 FY21 Q1 FY 21 Q4 FY21 Q1 FY22 • Q1 FY 22 Revenue Growth rate is partly on account of the low base during PAT the last financial
Slide 18: Financial Performance
FINANCIAL PERFORMANCE ROCE %(1) ROE %(2) 29.8% 25.2% 23.8% 26.9% 19.2% 18.5% FY20 FY21 Q1 FY22 FY20 FY21 Q1 FY22 Steady & consistent improvement in ROCE and ROE over last nine quarters 1. ROCE = Earning before interest and tax (EBIT) divided by capital employed (total aster – current liabilities), f
Slide 19: Financial Performance
FINANCIAL PERFORMANCE EBITDA % Matured & Acquired Matured Assets Tier II/III(1) Acquired Assets Tier II/III(2) 26.7 % 20.2 % 25.5 % 16.8% 23.1 % 5.5% FY 20 FY 21 Q1 FY 22 FY 20 FY 21 Q1 FY 22 The margins of the Acquired Assets in tier II / III are in line to grow to similar profile as that of the Ma
Slide 20: Financial Performance
FINANCIAL PERFORMANCE (RS. MILLIONS) Condensed Profit and Loss Statement Q1 FY 22 Vs Q1 FY 22 Vs Q1 FY 22 Q4 FY 21 Q1 FY 21 Q4 FY 21 (%) Q1 FY 21 (%) Total Income 4,775 3,627 2,055 32% 132% Material cost 1,123 773 430 45% 161% Doctor cost 873 729 378 20% 131% Employee benefit expenses 725 564 467 29
Slide 21: Financial Performance
FINANCIAL PERFORMANCE (RS. MILLIONS) Key Balance Sheet Items Key Balance Sheet details Q1 FY 22 Long Term Debt 2,092 Key Highlights Short Term Debt 57 Out of Rs. 2,000 Mn. raised through primary issue in June 2021, Rs. 1,500 Mn. had been Gross Debt 2,149 utilized for repayment of certain borrowings
Slide 22: Financial Summary
FINANCIAL SUMMARY 37% / 40% (3%) / (30%) Operating Performance IP / OP Volume Growth IP / OP Volume Growth (YoY Q1 FY22 Vs Q1 FY21) (QoQ Q1 FY22 Vs Q4 FY21) 31.0% / 19.5% EBITDA Margin 31.0% / 29.0% EBITDA Margin Financial Performance (YoY Q1 FY22 Vs Q1 FY21) (QoQ Q1 FY22 Vs Q4 FY21) As on 30th June
Slide 23: Next Steps
Next Steps • As mentioned earlier, we intend to focus on • Bangalore update: Because of lockdown large geographies that give us the scale as it restrictions, we weren’t able to complete did in AP & Telangana formalities in Q1. We are confident we will be • The markets identified were : Karnataka, ab
Slide 24: Growth Opportunity to Existing Facilities
GROWTH OPPORTUNITY TO EXISTING FACILITIES FY21 Beds Occupied % and Installed Capacity 1000 250 180 200 200 350 434 250 200 3,064 Overall occupancy of our 9 hospitals was at 58% in FY 21. 76% 76% 70% We see potential of 64% 58% occupancy going up 58% 58% 49% 50% further to the % seen 43% at matur
Slide 25: Journey of KIMS
JOURNEY OF KIMS KIMS Nellore established by Investment by Milestone Acquisition of 57.83% of the Acquisition of KIMS Ongole General Atlantic Invested, KIMS has successfully BRMH, it was transferred Private Equity Fund equity shareholding of by way of slump sale ICICI Ventures exited launched the IPO
Slide 26: Corporate Structure
CORPORATE STRUCTURE Krishna Institute of Medical Sciences Ltd. KIMS Secunderabad KIMS Nellore KIMS Rajahmundry KIMS Ongole (100%) (100%) (100%) (100%) AHPL KHEPL KIMS ICON KIMS Saveera KIMS Rainbow Srikakulam Kondapur Vizag Anantapur Kurnool (57.8%) (86.7%) (51.0%) (80.0%) (55.0%) 25 Private & Confi
Slide 27: Corporate Governance & Experienced Management Team
CORPORATE GOVERNANCE & EXPERIENCED MANAGEMENT TEAM Committed Board Experienced Management Team Dr. Bhaskara Rao Bollineni Mr. Saumen Chakraborty Managing Director, Independent Director, Chairman (CSRC) Chairman (Audit Committee) Dr. Bhaskara Rao Bollineni Dr. Abhinay Bollineni Vikas Maheshwari Manag
Slide 28: Shareholding Pattern - 30th June, 2021
SHAREHOLDING PATTERN - 30TH JUNE, 2021 Insurance Companies 3% Alternate Investment Funds 2% Mutual Fund 11% Promoters & Promoter Group 39% Foreign Portfolio Investor 12% Others 16% General Atlantic 17% 27 Private & Confidential
Slide 29: Thank You
Thank You 28 Private & Confidential
Krishna Institute of Medical Sciences — Q1 FY2022 Earnings Presentation on 6ix